

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



March 28, 2024

To whom it may concern

Company: TRYT Inc.
Representative: Hidetaka Sasai, President and Representative Director, CEO
(Securities code: 9164; Growth Market of the Tokyo Stock Exchange)
Contact: Takaaki Inoue, Managing Executive Officer, CFO, General Manager, Administration Department
Tel.: +81-6-6365-1131

Matters Concerning Controlling Shareholder, Etc.

TRYT Inc. (TRYT) hereby announces matters concerning controlling shareholder, etc. regarding LIFE SCIENCE & DIGITAL HEALTH CO. LIMITED, which is a controlling shareholder other than the parent company. The details are described below.

1. Trade name, etc. of parent, controlling shareholder (excluding parent), other affiliates or parent of other affiliates

(As of December 31, 2023)

Name	Attribute	Ownership ratio of voting rights (%)			Financial instruments exchange, etc. on which the issued shares, etc. are listed
		Directly owning portion	Portion subject to aggregation	Total	
LIFE SCIENCE & DIGITAL HEALTH CO. LIMITED	Controlling shareholder (excluding parent)	60.00	—	60.00	—

2. Matters concerning transactions with controlling shareholder, etc.

Not applicable.

3. Status of implementation of measures to protect minority shareholders in conducting transactions, etc. with controlling shareholder

In principle, TRYT does not conduct related party transactions, including transactions with a controlling shareholder. However, transactions may be conducted in cases where the transactions are deemed necessary from a business standpoint and the terms and conditions of the transactions are confirmed to be appropriate.

When conducting related party transactions, etc., TRYT's policy is to pay particular attention to whether it would be difficult to use an alternative means for the transactions, whether the economic rationality can be confirmed, whether the terms and conditions of the transactions are appropriate compared to other external transactions and do not provide benefits, etc., and other factors, conduct the transactions in accordance with the Internal Rules, and obtain the approval of the Board of Directors.